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Abstract
The follicular lymphoma cell line DoHH2, which over expresses BCL6 and has a wild type p53, 
was used to test the tumor suppressor activity of miR-34a. We transiently transfected miR-34a into 
DoHH2 cells and found that miR-34a failed to either induce apoptosis or reduce cell proliferation. 
To explain the lack of effect of miR-34a on cell proliferation we determined the expression of p53 
and  its  direct  target  p21.  Interestingly,  we  found  that  p53  strongly  diminished  in  miR-34a 
transfected cells both at transcriptional and post-transcriptional levels and that the down regulation 
of p53 was accompanied by a reduced transcription of p21. As BCL6 is a transcriptional repressor 
of p53 and p21 we cannot exclude that their down regulation following miR-34a over expression 
was due to an enhanced expression of BCL6. On the contrary we found that BCL6 decreased at 
both the mRNA and the protein levels in miR-34a transfected cells. We also found that miR-34 over 
expression determined a decrease in cMYC level. As it has been shown that cMYC controls p53 
expression  and  that  the  over  expression  of  miR-34a  caused  a  reduction  of  cMYC  level  we 
concluded that the down regulation of BCL6 was unable to displace the control of cMYC on p53 
and that the expected proapoptotic/antiproliferative activity of miR-34a was probably neutralized 
through the down regulation of cMYC and the consequent repression of p53. These data suggest 
that  cMYC has  a  pivotal  role  in  driving DoHH2 cell  proliferation by controlling p53. On this 
assumption we attempted to modify p53 without affecting cMYC levels. For that we silenced BCL6 
in DoHH2 cells using a previously reported effective siRNA and found that a 50% reduction of 
BCL6  protein  induced  the  up  regulation  of  p53  resulting  in  increased  apoptosis  and  a  partial 
inhibition of cell proliferation. The activation of p53 was confirmed by the up regulation of p21 and 
miR-34a but surprisingly cMYC was unaffected. The opposite results obtained by either BCL6 
silencing or over expressing miR-34a from one side suggest that acting on p53 without affecting 
cMYC expression is an effective strategy to hit the proliferation of DoHH2 cells and from the other 
side that the use of tumor suppressor miRNAs as cancer therapeutic molecules should take into 
account the gene expression network of target cells.
